11:45 AM EDT, 05/06/2024 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) shares surged more than 21% in recent Monday trading after the company's Q1 results topped estimates.

The company reported Q1 adjusted loss Monday of $0.17 per diluted share, narrowing from a loss of $0.28 a year earlier.

Analysts polled by Capital IQ expected a per-share loss of $0.23.

Revenue for the quarter ended March 31 was $92.8 million, up from $68.8 million a year earlier.

Analysts surveyed by Capital IQ expected $85.5 million.

The company said it continues to expect to approach quarterly positive EPS in the second half of 2025.

Price: 5.39, Change: +0.94, Percent Change: +21.12